The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome

Myelodysplastic syndrome (MDS) is a common hematological malignant disease, characterized by malignant hematopoietic stem cell proliferation in the bone marrow (BM); clinically, it mainly manifests clinically mainly by as pathological hematopoiesis, hemocytopenia, and high-risk transformation to acu...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 1078421
Main Authors Zheng, Likun, Zhang, Lei, Guo, Yixuan, Xu, Xintong, Liu, Zhaoyun, Yan, Zhenyu, Fu, Rong
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 07.12.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Myelodysplastic syndrome (MDS) is a common hematological malignant disease, characterized by malignant hematopoietic stem cell proliferation in the bone marrow (BM); clinically, it mainly manifests clinically mainly by as pathological hematopoiesis, hemocytopenia, and high-risk transformation to acute leukemia. Several studies have shown that the BM microenvironment plays a critical role in the progression of MDS. In this study, we specifically evaluated mesenchymal stromal cells (MSCs) that exert immunomodulatory effects in the BM microenvironment. This immunomodulatory effect occurs through direct cell-cell contact and the secretion of soluble cytokines or micro vesicles. Several researchers have compared MSCs derived from healthy donors to low-risk MDS-associated bone mesenchymal stem cells (BM-MSCs) and have found no significant abnormalities in the MDS-MSC phenotype; however, these cells have been observed to exhibit altered function, including a decline in osteoblastic function. This altered function may promote MDS progression. In patients with MDS, especially high-risk patients, MSCs in the BM microenvironment regulate immune cell function, such as that of T cells, B cells, natural killer cells, dendritic cells, neutrophils, myeloid-derived suppressor cells (MDSCs), macrophages, and Treg cells, thereby enabling MDS-associated malignant cells to evade immune cell surveillance. Alterations in MDS-MSC function include genomic instability, microRNA production, histone modification, DNA methylation, and abnormal signal transduction and cytokine secretion.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Immunological Tolerance and Regulation, a section of the journal Frontiers in Immunology
Edited by: Silvia Gregori, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Italy
These authors share first authorship
Reviewed by: Stefania Crippa, IRCCS San Raffaele Scientific Institute, Italy; Yizhou Zheng, Chinese Academy of Medical Sciences and Peking Union Medical College, China
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.1078421